Data Insights

IMGN-151 by ImmunoGen for Epithelial Ovarian Cancer: Likelihood of Approval

IMGN-151 is under clinical development by ImmunoGen and currently in Phase I for Epithelial Ovarian Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - IMGN-151 in Epithelial Ovarian Cancer

Data Insights

IMGN-151 by ImmunoGen for Peritoneal Cancer: Likelihood of Approval

IMGN-151 is under clinical development by ImmunoGen and currently in Phase I for Peritoneal Cancer. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - IMGN-151 in Peritoneal Cancer

Data Insights

IMGN-151 by ImmunoGen for Fallopian Tube Cancer: Likelihood of Approval

IMGN-151 is under clinical development by ImmunoGen and currently in Phase I for Fallopian Tube Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - IMGN-151 in Fallopian Tube Cancer

Data Insights

Pivekimab sunirine by ImmunoGen for Myeloproliferative Disorders: Likelihood of Approval

Pivekimab sunirine is under clinical development by ImmunoGen and currently in Phase I for Myeloproliferative Disorders. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Pivekimab Sunirine in Myeloproliferative Disorders

Data Insights

Pivekimab sunirine by ImmunoGen for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia): Likelihood of Approval

Pivekimab sunirine is under clinical development by ImmunoGen and currently in Phase II for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic...

Likelihood of Approval and Phase Transition Success Rate Model - Pivekimab Sunirine in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)

Data Insights

Pivekimab sunirine by ImmunoGen for Myelodysplastic Syndrome: Likelihood of Approval

Pivekimab sunirine is under clinical development by ImmunoGen and currently in Phase I for Myelodysplastic Syndrome. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Pivekimab Sunirine in Myelodysplastic Syndrome

Data Insights

Pivekimab sunirine by ImmunoGen for Relapsed Acute Myeloid Leukemia: Likelihood of Approval

Pivekimab sunirine is under clinical development by ImmunoGen and currently in Phase II for Relapsed Acute Myeloid Leukemia. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Pivekimab Sunirine in Relapsed Acute Myeloid Leukemia

Data Insights

Pivekimab sunirine by ImmunoGen for Refractory Acute Myeloid Leukemia: Likelihood of Approval

Pivekimab sunirine is under clinical development by ImmunoGen and currently in Phase II for Refractory Acute Myeloid Leukemia. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Pivekimab Sunirine in Refractory Acute Myeloid Leukemia

Data Insights

Pivekimab sunirine by ImmunoGen for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval

Pivekimab sunirine is under clinical development by ImmunoGen and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute Myeloblastic...

Likelihood of Approval and Phase Transition Success Rate Model - Pivekimab Sunirine in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)

Data Insights

Pivekimab sunirine by ImmunoGen for Blood Cancer: Likelihood of Approval

Pivekimab sunirine is under clinical development by ImmunoGen and currently in Phase II for Blood Cancer. According to GlobalData, Phase...